Authors
Latest:
House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing TacticsThe House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to ClassificationNuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Latest:
What We Learned About Biologics on Summer VacationIntellectual property law attorneys from the Washington, DC, offices of McDermott Will & Emery LLP, discuss 5 of the most significant trends in biologics litigation that have emerged in recent months.
Latest:
Opinion: Embrace the Era of Next-Generation BiologicsBincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.
Latest:
Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch UpDespite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.
Latest:
Making Patients in Canada Switch to Etanercept Biosimilars Caused No Harm or Changes in Health Care Use, Study FindsHealth Canada approved biosimilars Brenzys and Erelzi in August 2016 and April 2017, respectively. The study tracked effects of the first phase of the British Columbia Ministry of Health’s Biosimilar Initiative, which required patients to switch to biosimilars starting in May 2019.
Latest:
FDA Approves Third Pair of Denosumab BiosimilarsThe approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma DevelopmentSt John Skilton, PhD, vice president of product strategy and marketing at Protein Metrics, takes a deep dive into how the development of biosimilars is evolving and how tools, such as mass spectrometry, can help companies keep up with advancing technology.
Latest:
Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis BiosimilarsPharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and BeyondThe US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of BoneThe European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Latest:
Biosimilar Cases to Watch: Prolia/Xgeva and Denosumab CompetitorsThe denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation continues to shape the competitive landscape.
Latest:
Resources for Patients and Providers on Adalimumab BiosimilarsExpert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
Latest:
Updates on the Use of Biosimilars for Pediatric Patients With Rheumatic DiseaseAlthough more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.
Latest:
Americans Say Drug Costs Are Too High, and They Are RightThe executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.
Latest:
Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance EffortsCencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.
Latest:
Opinion: Purple Book Patent Listings Are Only a First StepIntellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar CompetitionIn response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.
